Braftovi

Generic name: Encorafenib
Dosage form: oral capsule
Drug class: Multikinase inhibitors

Usage of Braftovi

Braftovi (encorafenib) is an oral kinase inhibitor that may be used to treat certain types of cancer in combination with other medications. It is approved to treat adults:

with melanoma skin cancer with a confirmed BRAF V600E or V600K mutation that cannot be treated with surgery or has spread to other parts of the body (metastasized) in combination with binimetinib

who have had prior treatment for metastatic colorectal cancer with a confirmed BRAF V600E mutation, in combination with cetuximab

with metastatic non-small cell lung cancer (NSCLC) with a confirmed BRAF V600E mutation in combination with binimetinib.

Braftovi is only used for patients with an abnormal BRAF gene (this is a specific genetic marker). Your doctor will test you for this gene. This medicine is not for treating wild-type BRAF cancers, such as wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.

Braftovi was FDA-approved on June 27, 2018.

Braftovi side effects

Get emergency medical help if you have signs of an allergic reaction to Braftovi such as hives; difficulty breathing; or swelling of your face, lips, tongue, or throat.

Braftovi may cause serious side effects, including an increased risk of new skin cancers, such as cutaneous squamous cell carcinoma or basal cell carcinoma. Check your skin and tell your healthcare provider right away about any skin changes, including a:

new wart

skin sore or reddish bump that bleeds or does not heal

change in the size or the color of a mole.

Your healthcare provider should also check your skin before treatment, then every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin cancers.

Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that develop during treatment with Braftovi.

Some side effects are more likely to occur with Braftovi and binimetinib together.

Call your doctor at once if you develop:

eye pain or swelling, vision changes, seeing halos around lights, seeing color "dots" in your vision

a severe skin rash, skin pain or swelling, redness, and peeling skin on your hands or feet;

a fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out); or

signs of bleeding, such as weakness, dizziness, headache, nosebleeds, rectal bleeding, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds

signs of liver problems, such as yellowing of your skin or your eyes, dark or brown (tea-colored) urine, nausea or vomiting, loss of appetite, tiredness, bruising, or bleeding.

Common Braftovi side effects that affect more than 25% of patients, depending on the condition being treated include:

fatigue

nausea

diarrhea/constipation

dermatitis acneiform

cough

shortness of breath

vomiting

abdominal pain

joint pain

musculoskeletal pain

rash

visual impairment such as blurred vision.

Although this medicine is used to treat melanoma, using encorafenib may increase your risk of developing other types of skin cancer. Tell your doctor if you notice any new skin symptoms such as redness, warts, sores that will not heal, or a mole that has changed in size or color.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking Braftovi

You should not use Braftovi if you are allergic to encorafenib or any of the other ingredients in the capsules.

To make sure Braftovi is safe for you, tell your doctor if you have ever had:

heart problems including a condition called long QT syndrome (in you or a family member)

lung disease

liver or kidney disease

eye problems (especially a problem with your retina) or

bleeding problems, or a blood clot

have had bleeding problems

have been told that you have low blood levels of potassium, calcium, or magnesium

are pregnant or plan to become pregnant. Braftovi can harm your unborn baby.

This medicine may affect fertility (the ability to have children) in men.

Pregnancy

If you are a woman of childbearing potential, your healthcare provider will do a pregnancy test before you start taking Braftovi. Females who can become pregnant should use effective non-hormonal birth control (contraception) during treatment with Braftovi and for 2 weeks after the last dose.

Braftovi can make hormonal birth control less effective, including birth control pills, injections, implants, skin patches, and vaginal rings. To prevent pregnancy while using Braftovi, use a barrier form of birth control: condom, diaphragm, cervical cap, or contraceptive sponge. Talk to your healthcare provider about birth control methods that may be right for you during this time.

If you inadvertently become pregnant while taking Braftovi, tell your healthcare provider right away.

Breastfeeding

Do not breastfeed while using this medicine, and for at least 2 weeks after your last dose.

Relate drugs

How to use Braftovi

May be taken with or without food.

Avoid grapefruit during treatment with Braftovi. Grapefruit products may increase the amount of encorafenib in your body.

Usual adult dose for melanoma or NSCLC

450 mg orally once a day in combination with binimetinib.

Usual adult dose for colorectal cancer

300 mg orally once daily in combination with cetuximab.

Warnings

Although Braftovi is used to treat melanoma, it may increase your risk of developing other types of cancer including skin cancer. Ask your doctor about your specific risk. Tell your doctor if you notice any new skin or other symptoms. Your healthcare provider should check your skin before treatment with Braftovi, every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin or other cancers.

Braftovi can harm an unborn baby. Do not use it if you are pregnant. Your doctor may conduct a pregnancy test before you start treatment if you are a woman of childbearing age. Use a non-hormonal form of birth control to prevent pregnancy while using Braftovi and for at least 2 weeks after your last dose.

Avoid it in BRAF wild-type tumors because of the risk of increased cell proliferation.

May not be suitable for patients with cardiomyopathy when used in combination with binimetinib. Your healthcare provider will assess your left ventricular ejection fraction (LVEF) before initiating treatment, then after one month of treatment, and then every 2 to 3 months thereafter.

May cause liver toxicity when used in combination with binimetinib. Your healthcare provider will conduct liver function tests before treatment, and then monitor your liver function during treatment.

There is also a risk of major bleeding events, uveitis (inflammation inside the eye), and QT prolongation. Your doctor may perform certain tests before starting treatment, and then monitor you throughout treatment. Electrolyte abnormalities may need correcting before starting Braftovi. Braftovi is not recommended to be used as a single agent.

What other drugs will affect Braftovi

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, including:

Strong or moderate CYP3A4 inhibitors, such as clarithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir. Avoid coadministration, but if unavoidable, reduce the dosage of Braftovi

Strong or moderate CYP3A4 inducers, such as phenobarbital, phenytoin, rifampicin, St. John's Wort, or glucocorticoids. Avoid coadministration.

Sensitive CYP3A4 substrates, such as lenacapavir or hormonal contraceptives. Coadministration may increase the toxicity or decrease the efficacy of these agents. Avoid hormonal contraceptives.

Substrates of OATP1B1, OATP1B3, or BCRP transporters, such as statins, rifampicin, bosentan, valsartan, and thyroid hormones. Dose reductions may be required.

Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. See the prescribing information for a full list of interactions.

Popular FAQ

Braftovi is used in combination with other drugs to treat patients with advanced melanoma, advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer with BRAF gene mutations. Continue reading

Mektovi is used in combination with another medicine called encorafenib (Braftovi) to treat advanced forms of melanoma (skin cancer) and non-small cell lung cancer with certain BRAF gene mutations. Continue reading

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.